Abstract Number: 2844 • 2015 ACR/ARHP Annual Meeting
Secukinumab Reduces the Burden of Nail and Skin Disease in Patients with Psoriasis and Patients with Psoriatic Arthritis: Results from Two Phase 3 Studies
Background/Purpose: Nail psoriasis is associated with decreased finger mobility and pain in patients (pts) with moderate to severe plaque psoriasis and psoriatic arthritis (PsA).1,2 Secukinumab,…Abstract Number: 2853 • 2015 ACR/ARHP Annual Meeting
Secukinumab Improves Skin Symptoms and Physical Functioning Compared with Ustekinumab in Patients with Moderate to Severe Psoriasis with Concomitant Psoriatic Arthritis: Subanalysis of a Randomized, Double Blind, Parallel-Group, Active Comparator-Controlled Phase 3b Trial
Background/Purpose: Psoriatic arthritis (PsA) is a common comorbidity in patients (pts) with psoriasis. In the ongoing Phase 3b CLEAR study (NCT02074982), secukinumab, a fully human…Abstract Number: 3163 • 2015 ACR/ARHP Annual Meeting
The Smoking Paradox in the Development of Psoriatic Arthritis Among Psoriasis Patients
Background/Purpose: Smoking is a strong risk factor of psoriasis, but a previous study has suggested that smoking protects against the development of psoriatic arthritis (PsA)…Abstract Number: 660 • 2015 ACR/ARHP Annual Meeting
Comparison of the Four Validated Psoriatic Arthritis Screening Tools in Diagnosing Psoriatic Arthritis in Patients with Psoriasis [Compaq Study]
Background/Purpose: Although there are various Psoriatic arthritis (PsA) screening questionnaires, the most optimal screening instrument is not known. The objective of the present study was…Abstract Number: 673 • 2015 ACR/ARHP Annual Meeting
Characterization of Psoriatic Arthritis [Psa] in a Large, Integrated Health Plan: Demographics, Referral Patterns and Care Management
Background/Purpose: Despite guidelines and evidence indicating that early diagnosis and treatment of PsA is critical, few studies have described referral and care-management patterns in a…Abstract Number: 1242 • 2015 ACR/ARHP Annual Meeting
Germ Line DNA Methylation Profiling Provides Novel Insights into the Parent-of-Origin Effect in Psoriatic Disease
Background/Purpose: Parent-of-origin effects refer to the differential risk or pathogenicity of a disease that depends on the sex of the disease-transmitting parent. Excessive paternal transmission…Abstract Number: 1692 • 2015 ACR/ARHP Annual Meeting
Serious Infections in Psoriasis Patients with Psoriatic Arthritis in the Psoriasis Longitudinal Assessment and Registry Study
Background/Purpose: To describe the rates of serious infections in psoriasis patients with psoriatic arthritis(PsA) from PSOLAR. Methods: PSOLAR is an international, disease-based, observational study in…Abstract Number: 1694 • 2015 ACR/ARHP Annual Meeting
All-Cause Mortality and Malignancies in Psoriasis Patients with Psoriatic Arthritis in the Psoriasis Longitudinal Assessment and Registry Study
Background/Purpose: Describe characteristics and incidence rates of all-cause mortality and malignancies (excluding NMSC) in psoriasis pts with psoriatic arthritis (PsA) from PSOLAR. Methods: PSOLAR is…Abstract Number: 1589 • 2014 ACR/ARHP Annual Meeting
Risk of Opportunistic Infection and Herpes Zoster Infection in a Psoriasis/Psoriatic Arthritis Cohort
Background/Purpose: Psoriasis/Psoriatic arthritis (PsO/PsA) often requires treatment with systemic agents. Some of these agents are associated with infectious adverse events. Few studies have described the…Abstract Number: 1600 • 2014 ACR/ARHP Annual Meeting
Is There a Role for Inflammasome Activation in PsA Pathogenesis and Its Comorbidities?
Background/Purpose . New data has emerged about the role of the inflammasome in psoriasis and psoriatic arthritis (PsA). The assembly of the inflammasome components in…Abstract Number: 1563 • 2014 ACR/ARHP Annual Meeting
Malignancies in the Psoriasis Longitudinal Assessment and Registry Study: Cumulative Experience
Background/Purpose To report the cumulative incidence of malignancies excluding non-melanoma skin cancers (NMSC) in the PSOLAR study. Methods PSOLAR is a multicenter, longitudinal, observational study…Abstract Number: 1569 • 2014 ACR/ARHP Annual Meeting
Persistence of Biologic Therapy in Psoriatic Disease: Results from the Psoriasis Longitudinal Assessment and Registry
Background/Purpose We evaluated persistency (treatment longevity) of biologics in patients (pts) with psoriasis (PsO), as well as with psoriatic arthritis (PsA) in the context of…Abstract Number: 1546 • 2014 ACR/ARHP Annual Meeting
Risk of Non Melanoma Skin Cancer Among Medicare Psoriasis/Psoriasis Arthritis Patients
Background/Purpose: Many systemic treatments for psoriatic arthritis and psoriasis (PsA/PsO) are immune-modulating, which may increase the risk of non-melanoma skin cancer (NMSC). However, the comparative…Abstract Number: 1562 • 2014 ACR/ARHP Annual Meeting
Psoriasis Longitudinal Assessment and Registry: Global Update upon Full Enrollment
Background/Purpose To report the baseline demographics and clinical characteristics of participants enrolled in the Psoriasis Longtitudinal Assessment and Registry (PSOLAR) study. Methods PSOLAR is a…Abstract Number: 1184 • 2014 ACR/ARHP Annual Meeting
Subclinical Inflammation in Psoriatic Patients with No History of Psoriatic Arthritis: An Assessment By Magnetic Resonance Imaging
Background/Purpose Six to 39% of patients with cutaneous psoriasis (PSO) can develop psoriatic arthritis (PsA). The transition from skin disease to joint involvement is only…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- Next Page »